abcl-20251110
0001703057falseVancouverBC00017030572025-11-102025-11-10

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
__________________________________________
FORM 8-K
__________________________________________
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d)
OF THE SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): November 10, 2025
__________________________________________
AbCellera Biologics Inc.
(Exact name of registrant as specified in its charter)
__________________________________________
British Columbia001-39781Not Applicable
(State or other jurisdiction of incorporation)(Commission File Number)(IRS Employer Identification Number)
150 W 4th Avenue
Vancouver, BC
V5Y 1G6
(Address of registrant’s principal executive office)(Zip code)
(604) 559-9005
(Registrant’s telephone number, including area code)
(Former name or former address, if changed since last report)
__________________________________________
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
oWritten communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
oSoliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
oPre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
oPre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading symbol(s)Name of each exchange on which registered
Common sharesABCLThe Nasdaq Stock Market LLC
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company  o
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  o


Item 5.02    Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

Appointment of Director
On November 10, 2025, the Board of Directors (the "Board") of AbCellera Biologics Inc. (the "Company") appointed Stephen Quake, D.Phil. as a new director, effective immediately. Dr. Quake will serve until the Company’s next annual meeting of shareholders and until his successor is duly elected and qualified, or until his earlier resignation or removal.

The Board has affirmatively determined that Dr. Quake is independent under the rules of The NASDAQ Stock Market LLC and the Company’s Corporate Governance Guidelines. Dr. Quake has been appointed to the Audit Committee and the Nominating and Corporate Governance Committee.

In connection with Dr. Quake’s service as a director, he will participate in the Company's Non-Employee Director Compensation Policy on the same terms as the Company’s other non-employee directors, as previously disclosed in the Company's Definitive Proxy on Schedule 14A filed with the Securities and Exchange Commission on April 29, 2025.

Dr. Quake has no direct or indirect material interest in any transaction pursuant to Item 404(a) of Regulation S-K.

Director Resignation
On November 10, 2025, Andrew Lo, Ph.D. resigned from the Board, effective immediately. Dr. Lo’s resignation was not the result of any disagreement with the Company. Dr. Lo joined the Board in December 2021 and served on the Audit and Nominating and Corporate Governance Committees. The Board would like to thank Dr. Lo for his leadership and service to the Company.

A copy of the press release is attached hereto as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

Item 9.01    Financial Statements and Exhibits
(d)Exhibits
Exhibit
No.		Description
99.1
104Cover Page Interactive Data File (embedded as Inline XBRL document)


SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 12, 2025ABCELLERA BIOLOGICS INC.
 
By:/s/ Carl L. G. Hansen
Carl L. G. Hansen, Ph.D.
Chief Executive Officer and Director
(Principal Executive Officer)

150 W 4th Ave Vancouver, BC V5Y 1G6 T 1. 604.559.9005 abcellera.com NEWS RELEASE AbCellera Appoints Dr. Stephen Quake to its Board of Directors 2025-11-10 VANCOUVER, British Columbia--(BUSINESS WIRE)-- AbCellera (Nasdaq: ABCL) today announced the appointment of Stephen Quake, D.Phil., to its Board of Directors as an independent director. Dr. Quake is a distinguished scientist, inventor, and entrepreneur who has made foundational contributions across diverse �elds, including single molecule biophysics, micro�uidics, single cell analysis, genomics, molecular diagnostics, and non-invasive prenatal testing. His work is represented in over 300 publications (h-index of 181) and 80+ patents and patent applications. “We are pleased to welcome Dr. Quake to AbCellera’s Board of Directors. His presence reinforces our commitment to excellence in science and technology,” said Carl Hansen, Ph.D., founder and CEO of AbCellera. “He brings a distinctive combination of scienti�c breadth, creativity, and interdisciplinarity that resonates with AbCellera’s culture and strategy.” Dr. Quake is currently the Lee Otterson Professor of Bioengineering and Professor of Applied Physics at Stanford University and was previously the Thomas and Doris Everhart Professor of Applied Physics and Physics at Caltech. He has been elected to four U.S. national academies: the National Academies of Sciences, Engineering, Medicine, and Inventors. In 2025, Dr. Quake was elected as a Foreign Member of the Royal Society. Dr. Quake was the founding co-president of the Chan Zuckerberg Biohub starting in 2016 and later became 1

 
president of the Chan Zuckerberg Biohub Network and Head of Science for the Chan Zuckerberg Initiative until 2025. Under his leadership, the Biohub had a launch budget of approximately $600 million and delivered on foundational large-scale science programs, including several whole organism Single Cell Atlases. As an entrepreneur, Dr. Quake has cofounded more than a dozen companies developing products in �elds of micro�uidics, genomics, molecular diagnostics, and therapeutics. “I greatly admire what Carl and the AbCellera team have accomplished to date, and I’m thrilled to join the team and be a part of it going forward,” said Dr. Quake. Dr. Quake received a B.S. in Physics and M.S. in Mathematics from Stanford University and a doctorate in Theoretical Physics from the University of Oxford. Concurrent with Dr. Quake’s appointment, Andrew W. Lo, Ph.D., will be resigning as independent director. Dr. Lo, a cofounder of BridgeBio Pharma and the Charles E. and Susan T. Harris Professor of Finance at the MIT Sloan School of Management, joined the Board in December 2021 and served on Audit and Nominating and Corporate Governance Committees. “It has been a pleasure to work with Andrew over the past four years. His guidance and unique �nancial insights have meaningfully contributed to advancing AbCellera’s business and strategy,” said Dr. Hansen. “Our team and board thank Andrew for his leadership and wish him the best in his future endeavors.” About AbCellera Biologics Inc. AbCellera (Nasdaq: ABCL) is a clinical-stage biotechnology company focused on discovering and developing antibody-based medicines in the areas of endocrinology, women’s health, immunology, and oncology. For more information, please visit www.abcellera.com. Inquiries Media: Tiffany Chiu; [email protected], +1(236)521-6774 Partnering: Murray McCutcheon, Ph.D.; [email protected], +1(604)559-9005 Investor Relations: Peter Ahn; [email protected], +1(778)729-9116 Source: AbCellera Biologics Inc. Source: AbCellera Biologics Inc. 2